id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S17504 R73559 |
Wiggs, 2024 | Cleft lip and cleft palate | early pregnancy | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 2.65 [0.92;7.66] | -/624 -/12,666 | - | 624 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7663 R22688 |
Tomson (Valproate), 2018 | Cleft lip or palate | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 3.65 [0.91;14.63] C | 6/1,381 3/2,514 | 9 | 1,381 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S318 R14440 |
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 | Facial cleft | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 11.29 [2.54;50.12] | 13/1,220 2/2,098 | 15 | 1,220 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10732 R39684 |
De Jonge (Valproate), 2013 | Oral clefts | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 0.76 [0.05;12.28] C | 0/65 294/29,452 | 294 | 65 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5940 R23802 |
Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 | Oral clefts | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 2.79 [0.81;9.57] C | 4/323 7/1,562 | 11 | 323 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 3.44 [1.86;6.36] | 329 | 3,613 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate; 2: Valproate) (Controls exposed to Lamotrigine, sick; 3: Valproate; 4: Valproate) (Controls exposed to Lamotrigine, sick;
Asymetry test p-value = 0.7494 (by Egger's regression)
slope=1.6792 (1.3158); intercept=-0.6566 (1.8757); t=0.3501; p=0.7494
excluded